Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Editorial comment

Cummings, C. Christiansen(University of Copenhagen), Cesar Libanati(Amgen (United States)), José Zanchetta(Universidad del Salvador), Suresh Siddhanti(Amgen (United States)), E. S. Siris, Richard Eastell(University of Sheffield), Štěpán Kutílek, A Wang, Melissa A. Austin(Thomas Jefferson University Hospital), Silvano Adami(University of Verona), IR Reid, P. D. Delmas(Inserm), J E Martin, Hb Zoog, Mccloug
Unknown
January 1, 2009
Cited by 0

Related Papers

Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2001|4.6k
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
|New England Journal of Medicine|2014|1.2k
Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial
|The Lancet|2009|837
Efficacy of Bazedoxifene in Reducing New Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis: Results From a 3-Year, Randomized, Placebo-, and Active-Controlled Clinical Trial
|Journal of Bone and Mineral Research|2008|508